GSK_Annual_Report_2021

Statutory Reports GlaxoSmithKline Pharmaceuticals Limited 20 Revenue from Operations* ( ` Crores) 2017-18 (12 Months) 2018-19 (12 Months) 2019-20 (12 Months) 2020-21 (12 Months) 2016-17 (12 Months) 2017-18 (12 Months) 2018-19 (12 Months) 2019-20 (12 Months) 2020-21 (12 Months) 2016-17 (12 Months) 2017-18 (12 Months) 2018-19 (12 Months) 2019-20 (12 Months) 2020-21 (12 Months) 2016-17 (12 Months) 2995 2896 3129 3225 3194 Net Profit for the Period ( ` Crores) * Without considering exceptional items, the net profit % for the period 2019-20 would be 14% and for the period 2020-21 would be 17% respectively Net Pr ofit for the Period and % to Revenue from Operations 337 352 425 110 358 11% * 3%* 14% 12% 11% Earnings Per Share (EPS) and Book Value Per Share 2017-18 (12 Months) 2018-19 (12 Months) 2019-20 (12 Months) 2020-21 (12 Months) 2016-17 (12 Months) 2017-18 (12 Months) 2018-19 (12 Months) 2019-20 (12 Months) 2020-21 (12 Months) 2016-17 (12 Months) Book value EPS 120 19.9* 20.8* 25.1* 6.5** 21.1** 123 126 109 90 * Retrospectively adjusted for September 2018 bonus issue for all the prior years ** Without considering exceptional items, Earnings per equity share for the period 2019-20 would be 26.69 and 2020-21 would be 31.32 respectively Profit Before Tax and % to Revenue from Operations PBT ( ` Crores) % to Revenue from Operations * Without considering exceptional items, the profit before tax % for the period 2019-20 would be 20% and 2020-21 would be 23% respectively 542 664 322 550 17% 19% 21% 10%* 17%* EBITDA ( ` Crores) % to Revenue from Operations 14% 18% 20% 21% 22% 695 EBITDA (Excl. Exceptional Items) and % to Revenue from Operations 420 510 631 658 Utilisation of Income* * % Utilisation of Income excludes Exceptional Income Contribution to Exchequer 6% Materials 40% Depreciation 2% % to Revenue from Operations ( ` ) *In accordance with Ind AS and Schedule III of Companies Act, 2013, GST is not part of Revenue. Accordingly, the revenue from operations for the period 2017-18, 2018-19, 2019-20 and 2020-21 are not comparable with the previous periods wherein excise duty was included. 511 Surplus retained in business or attributable towards dividends 11% Exceptional Items (net) 5% Operating Expenses 36% Financial highlights